In another in vivo study of a BC mouse model, treatment with anti-CTLA-4 antibody delayed tumor growth, and anti-CTLA-4 antibody plus matrix metalloproteinase inhibitor therapy reduced the percentage of Tregs, Th17 cells, and MDSCs in tumors compared with the control group.295. This evidence concerns the gene CTLA4 and breast cancer.